Contents
Vol 11, Issue 539
Research Articles
- Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia
Dasatinib or TNK2-specific inhibitors may treat PTPN11-mutant leukemia.
- Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization
High-efficacy opioids enhance receptor desensitization due to rapid and sustained GRK2/β-arrestin interactions.
- Unique BIR domain sets determine inhibitor of apoptosis protein–driven cell death and NOD2 complex signal specificity
The unique positioning of similar domains determines the signaling specificity of IAP family proteins.
Editors' Choice
- CRISPR, cancer, and p53
CRISPR-Cas9 genome editing is most efficient in cells lacking functional p53 protein, a phenotype common to cancer cells.
About The Cover

Online Cover This week features a Research Article that shows that the drug dasatinib slows the growth of two types of leukemia (JMML and AML) and extended survival in a patient. The image shows white blood cells. [Image: jarun011/iStock]